Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors

Abstract Background Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma but are associated with immune‐related adverse events (irAEs). This single center, cross‐sectional survey aimed to describe the long‐term symptom burden and impact on health‐related qual...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	E. L. Looman, P. F. Cheng, J. Lai‐Kwon, L. Morgan, M. Wakkee, R. Dummer, F. Dimitriou
Format:	Article
Language:	English
Published:	Wiley 2023-06-01
Subjects:	immune checkpoint inhibitors immunotherapy melanoma quality of life survivorship
Online Access:	https://doi.org/10.1002/cam4.5967